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cords were reviewed from 2007 to 2009 to extract patients with principle diagnosis
of ICD-9 codes for cellulitis, abscess, postoperative and traumatic wound infec-
tions, and other conditions related to ABSSSI. We assessed inpatient utilization in
terms of LOS and ICU time, and inpatient costs stratified by initial antibiotic treat-
ment. We also assessed the frequency of in-hospital mortality and empiric treat-
ment failure. RESULTS: Inpatient treatment of ABSSSI increased by 15.4% from
2007 to 2009. In 2009, 110,457 ABSSSI patients were admitted to Premier hospitals,
with 65% admitted through the ER. The initial antibiotic treatment was vancomy-
cin (49.9%) and clindamycin (15.9%). The average LOS was 5.3 days. The average
cost per stay was $8000. The most costly departmental charges were room/board
($1000) and pharmacy ($650). 17.2% of patients failed on initial antibiotic treatment,
resulting in additional LOS of 5 days and $6000 per stay on average. With approx.
750K admissions for ABSSSI in the United States, this extrapolates to a US hospital
economic burden of $6 billion/yr. CONCLUSIONS: The economic burden of hos-
pitalization for ABSSSI in the United States is significant. Antibiotic treatments
offering the possibility of treating a greater proportion of patients currently hospi-
talized in an ambulatory or observational setting by avoiding or shortening hospi-
tal stays may significantly reduce the cost to the US health care system.
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OBJECTIVES: Congenital cytomegalovirus (CMV) infection during pregnancy are a
serious, yet not well recognized health problem. The aim of our study is to assess
the annual cost of diagnosis and prevention of congenital cytomegalovirus infec-
tion by Cytotect in Hungary.METHODS:We built a model on estimating the costs.
Data on deliveries derived from the database of the Hungarian Central Statistical
Office. Cost items were calculated according to the standard reimbursement list of
the Hungarian National Health Insurance Fund, the only health care financing
agency in Hungary. The number of livebirths was 90,335 in 2010 in Hungary. The
cost of CMV Ig-test was 2 Euro. Average bodyweight was 80 kg, the average dosis of
Cytotec was 8000 unit or 80 ml per patient with a cost of 8 Euro per ml. CMV-
seronegative women (40 % of all deliveries) are the high risk group applying 4 tests
during pregnancy. Seroconversion rate was 1 %. RESULTS: For all pregnant women
(N90335), the total annual cost of diagnosis of congenital cytomegalovirus infec-
tion was calculated 180,670 Euro (or 54.2 million Hungarian Forint). For CMV-sero-
negative high risk women (N36134) the total annual cost of diagnosis was as-
sessed 289072 Euro (or 86.7 million Hungarian Forint). The cost of prevention of all
women with primary infection during pregnancy was 2.89 million Euro (or 867.2
million Hungarian Forint). CONCLUSIONS: Both the diagnosis and prevention of
congenital cytomegalovirus (CMV) infection during pregnancy represents a reason-
able cost in Hungary. Further study should focus on the effectiveness of preven-
tion.
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OBJECTIVES: The use of combined tetanus toxoid, reduced diphtheria toxoid, and
acellular pertussis vaccine (Tdap) in pregnant and postpartum women provides
personal protection and may reduce the risk of transmission of pertussis to their
young infants. The study seeks to assess the economic benefits associated with a
hospital-based postpartum Tdap vaccination strategy. METHODS: A decision tree
model was constructed to calculate the potential cost-benefit of this strategy from
a health care system or societal perspective. Probabilities and costs were derived
from published literature, Centers for Disease Control and Prevention data, and
expert recommendations. The maternal vaccination protection period for infants
was defined as 7 months, as the infants do not receive a full series of pertussis
immunization before 6 months of age, with 1 month added for maximal develop-
ment of immunity. 10-year vaccine protection for birth mothers was estimated in
the model. All cost estimates were inflated to year 2010 US dollars and discounted
at a 3% annual discount rate. RESULTS: From a societal perspective, the average
costs per vaccinated and unvaccinated mother were estimated at $132.92 and
$232.75, respectively. Our model suggests an expected net benefit (ENB) of $99.83
per postpartum vaccinated mother. The overall societal benefits in the cohort of
U.S. birth mothers ranged from $89.8  $287.5 million, depending on the vaccine
coverage rate. If including direct medical costs only, the ENB was estimated at
-$27.26 per vaccinatedmother, suggesting that this strategy is not cost-saving from
a health care system perspective. Annual incidence in birth mothers and Tdap
efficacy exhibited substantial impact on the model from one-way and two-way
sensitivity analyses. CONCLUSIONS: Postpartum Tdap vaccination is likely to gen-
erate net benefits in the base case from a societal perspective, if the annual inci-
dence of pertussis among birth mothers exceeds 140 cases per 100,000.
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BACKGROUND: In US treatment guidelines, efavirenz (EFV) is the preferred non-
nucleoside reverse transcriptase inhibitor (NNRTI) for first-line treatment of HIV. In
the ECHO and THRIVE trials comparing EFV with another NNRTI, rilpivirine (RPV),
both medications had similar rates of virologic suppression at 96-weeks; however,
RPV had higher rates of virologic failure and drug resistance and lower rates of
discontinuation due to adverse events. OBJECTIVES: To estimate the cost-effec-
tiveness of EFV versus RPV in first-line HIV treatment in the US. METHODS: A
Markovmodel with 14 health states was constructed to estimate 10-year costs and
clinical outcomes from a US payer perspective for antiretroviral naïve HIV patients
initiating EFV or RPV. First-line efficacy data came from 96-week results of the
ECHO and THRIVE trials, which compared EFV and RPV, both in combination with
two nucleos(t)ide reverse transcriptase inhibitors. Other clinical inputs, mortality
rates and costs (2011 US$) came from published sources. Subsequent therapy lines
(second, third, non-suppressive) were based on US treatment guidelines and com-
mon to both treatment arms. Robustness of study results was assessed in sensi-
tivity analyses that varied model inputs by 25%. RESULTS: In the base case, total
costs over 10 years were lower for EFV versus RPV ($214,031 versus $222,090). Life
expectancy (8.44 years) and life years without AIDS (8.40 years) were the same and
life years in virologic suppression were similar (EFV 7.87 years, RPV7.86 years).
EFV was modestly cost-saving versus RPV in terms of incremental cost-effective-
ness per life-year gained, per life-year gained in viral suppression, and per life-year
gainedwithout AIDS. In sensitivity analyses, EFV remained cost-saving versus RPV
more than 90% of the time, demonstrating the robustness of study results.
CONCLUSIONS: Over a 10-year time horizon, EFV was predicted to be modestly
cost-saving compared with RPV in HIV patients initiating first-line treatment in
the US.
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OBJECTIVES: To evaluate the comparative cost-effectiveness of sequential i.v./p.o.
CAP treatment with moxifloxacin versus amoxicillin/clavulanic acid (AMCLA),
ceftriaxone amoxicillin/clavulanic (CEFAMCLA) acid and cefotaxime macro-
lides (COMB) in adult patients. METHODS: Patients were randomized in four
groups. MOX group received moxifloxacin 400 mg i.v. once-daily with further
switch to p.o. formulation 400 mg daily. AMCLA group received amoxicillin/clavu-
lanic acid 1200 mg i.v. once-daily with further switch to p.o. formulation 1000 mg
twice-daily. CEFAMCLA group received ceftriaxone 1000 mg i.v. once-daily with
further switch to amoxicillin/clavulanic acid 1000 mg p.o. twice daily. COMB group
received either cefotaxime 1000 mg i.m. 3 times per day as monotherapy or in
combination with oral azithromycin or clarithromycin. Efficacy and safety criteria
were evaluated according to clinical data, laboratory tests and X-ray examination.
Cost-effectiveness analysis was performed. RESULTS: MOX group included 30 pa-
tients, mean age 33.616.5 years; AMCLA group included 30 patients, mean age
27,115,4 years; CEF/AMCLA group included 47 patients, mean age 23,59,6 years;
COMB group included 50 patients, mean age 26.515.6 years. The efficacy of treat-
ment and in-hospital stay duration were: 96.7% and 15.12.1 days in MOX group,
93.3% and 17,02,7 days in AMCLA group, 95.7% and 16,43,4 days in CEF/AMCLA
group, 88.0% and 18.23.7 days in COMB group. Direct medical costs including
antibacterial treatment and in-hospital days were $1536 in MOX, $1540 in AMCLA,
$1502 in CEF/AMCLA and $1671 in COMB group. CERMOX 1589$, CERAMCLA1650$,
CERCEF/AMCLA1570$, CERCOMB 1899$. CONCLUSIONS: Sequential CAP treatment
with moxifloxacin compared to other alternatives in adult patients is the most
effective, convenient and compliant therapy. In terms of cost-effectiveness, it
dominants over AMCLA and COMB treatment and have the comparable costs with
CEFAMCLA group.
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OBJECTIVES: Telaprevir is a new direct acting antiviral for the treatment of geno-
type 1 hepatitis C virus (HCV) infection. This analysis evaluated the cost-effective-
ness of TVR/PR therapy compared to PR alone in treatment-naïve and previously
treated G1 chronic HCV patients. Cost-effectiveness is considered in terms of in-
cremental cost per quality-adjusted life-year (QALY) gained from the perspective of
the NHS in Scotland. METHODS: Two Markov models were developed to evaluate
treatments studied in TVR phase III clinical trials: TVR response-guided therapy of
12weeks of TVRwith PR [24weeks PR for patients achieving an extended rapid viral
response (eRVR), 48 weeks of PR for patients not achieving an eRVR] for treatment-
naïve patients; 12 weeks of TVR in combination with 48 weeks of PR therapy for
treatment-experienced patients. SVR rates of 75% and 44% for TVR/PR and PR alone
respectively are taken from the TVR12/PR and PBO/PR treatment arms in the AD-
VANCE trial. SVR rates of 83%, 59% and 29% for TVR/PR and 24%, 15% and 5% for PR
alone in prior relapse, prior partial response and prior null response patients, re-
spectively are taken from the TVR12/PR and PBO/PR treatment arms in the REALIZE
trial. RESULTS: The analysis shows higher costs and improved outcomes associ-
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